Mirum Pharmaceuticals 過去の業績

過去基準チェック /06

Mirum Pharmaceuticalsの収益は年間平均-12.9%の割合で減少していますが、 Biotechs業界の収益は年間増加しています。収益は年間19.3% 73.5%割合で増加しています。

主要情報

-12.9%

収益成長率

13.6%

EPS成長率

Biotechs 業界の成長	17.0%
収益成長率	73.5%
株主資本利益率	-43.0%
ネット・マージン	-32.5%
前回の決算情報	30 Sep 2024

Recent updates

Analysts Are Updating Their Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM) Estimates After Its Third-Quarter Results

Nov 15

Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM) Shares Fly 46% But Investors Aren't Buying For Growth

Jul 13

Mirum Pharmaceuticals, Inc.'s (NASDAQ:MIRM) Business And Shares Still Trailing The Industry

May 28

Mirum Pharmaceuticals: After Phase 2 Miss, An iBAT Inhibitor On Deck To Drive Value

Apr 22

Mirum Pharmaceuticals: Advancing On Several Key Fronts

Mar 05

There's Reason For Concern Over Mirum Pharmaceuticals, Inc.'s (NASDAQ:MIRM) Price

Dec 26

What Mirum Pharmaceuticals, Inc.'s (NASDAQ:MIRM) P/S Is Not Telling You

Jun 10

Industry Analysts Just Made A Captivating Upgrade To Their Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM) Revenue Forecasts

Apr 18

Mirum's liver disease drug Livmarli gets EMA committee nod for approval in EU

Oct 14

Mirum: Great Sales Start For Livmarli Paves The Way For Long-Term Growth

Aug 17

Mirum Pharmaceuticals announces $80M stock offering

Aug 09

Mirum Pharmaceuticals: Post-Approval Execution Looks Excellent

May 27

収支内訳

Mirum Pharmaceuticals の稼ぎ方とお金の使い方。LTMベースの直近の報告された収益に基づく。

収益と収入の歴史

NasdaqGM:MIRM 収益、費用、利益 ( )USD Millions
日付	収益	収益	G+A経費	研究開発費
30 Sep 24	307	-100	192	128
30 Jun 24	264	-109	178	122
31 Mar 24	224	-159	161	111
31 Dec 23	186	-163	146	103
30 Sep 23	145	-164	126	103
30 Jun 23	116	-176	112	103
31 Mar 23	96	-129	100	106
31 Dec 22	77	-136	89	107
30 Sep 22	52	-42	82	104
30 Jun 22	39	-53	76	108
31 Mar 22	32	-70	69	117
31 Dec 21	19	-84	59	131
30 Sep 21	16	-179	47	133
30 Jun 21	11	-153	36	119
31 Mar 21	0	-132	27	102
31 Dec 20	0	-103	23	82
30 Sep 20	0	-84	20	66
30 Jun 20	0	-78	18	62
31 Mar 20	0	-68	15	55
31 Dec 19	0	-53	12	43
30 Sep 19	0	-61	8	32

質の高い収益: MIRMは現在利益が出ていません。

利益率の向上: MIRMは現在利益が出ていません。

フリー・キャッシュフローと収益の比較

過去の収益成長分析

収益動向: MIRMは利益が出ておらず、過去 5 年間で損失は年間12.9%の割合で増加しています。

成長の加速: MIRMの過去 1 年間の収益成長を 5 年間の平均と比較することはできません。現在は利益が出ていないためです。

収益対業界: MIRMは利益が出ていないため、過去 1 年間の収益成長をBiotechs業界 ( 16.6% ) と比較することは困難です。

株主資本利益率

高いROE: MIRMは現在利益が出ていないため、自己資本利益率 ( -43.02% ) はマイナスです。

Mirum Pharmaceuticals 過去の業績

過去 基準チェック /06

主要情報

最近の業績更新

Mirum Pharmaceuticals, Inc. to Report Q3, 2024 Results on Nov 12, 2024

Mirum Pharmaceuticals, Inc. to Report Q2, 2024 Results on Aug 07, 2024

Mirum Pharmaceuticals, Inc. to Report Q1, 2024 Results on May 08, 2024

Mirum Pharmaceuticals, Inc. to Report Q4, 2023 Results on Feb 28, 2024

Third quarter 2023 earnings: EPS and revenues exceed analyst expectations

Second quarter 2023 earnings: Revenues exceed analysts expectations while EPS lags behind

Recent updates

Analysts Are Updating Their Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM) Estimates After Its Third-Quarter Results

Mirum Pharmaceuticals, Inc. to Report Q3, 2024 Results on Nov 12, 2024

Is Mirum Pharmaceuticals (NASDAQ:MIRM) Using Too Much Debt?

Mirum Pharmaceuticals Receives FDA Breakthrough Therapy Designation for Volixibat in Treating Cholestatic Pruritus in PBC

Mirum Pharmaceuticals: Intriguing, But Wait For Volixibat Data Makes Me Bearish

Mirum Pharmaceuticals, Inc. to Report Q2, 2024 Results on Aug 07, 2024

Mirum Pharmaceuticals, Inc’s LIVMARLI Now Approved for PFIC in Patients 12 Months and Olderer

Bullish On Mirum Pharmaceuticals: Enhanced Portfolio With Strategic Acquisition

Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM) Shares Fly 46% But Investors Aren't Buying For Growth

Mirum Pharmaceuticals, Inc.' LIVMARLI Approves in the European Union for Patients with PFIC

Mirum Pharmaceuticals Announces Positive Chmp Opinion for Livmarli® (Maralixibat) Oral Solution for the Treatment of Pfic in Patients Three Months of Age and Older

Mirum Pharmaceuticals, Inc.'s (NASDAQ:MIRM) Business And Shares Still Trailing The Industry

Forecast breakeven date pushed back to 2026

Mirum Pharmaceuticals, Inc Publication of Phase 3 MARCH Data in The Lancet Demonstrating Benefits of LIVMARLI (maralixibat) in patients with PFIC

Mirum Pharmaceuticals, Inc. to Report Q1, 2024 Results on May 08, 2024

Mirum Pharmaceuticals, Inc., Annual General Meeting, Jun 05, 2024

Mirum Pharmaceuticals: After Phase 2 Miss, An iBAT Inhibitor On Deck To Drive Value

Mirum Pharmaceuticals, Inc. receives Positive Reimbursement Recommendation for Livmarli (Maralixibat Oral Solution) by Canada’S Cadth for Patients with Cholestatic Pruritus in Alagille Syndrome

Mirum Pharmaceuticals, Inc. Announces U.S. Food and Drug Administration Approve LIVMARLI (Maralixibat) Oral Solution for the Treatment of Cholestatic Pruritus in Patients Five Years of Age and Older with Progressive Familial Intrahepatic Cholestasis

Mirum Pharmaceuticals: Advancing On Several Key Fronts

Mirum Pharmaceuticals, Inc. announced delayed annual 10-K filing

Mirum Pharmaceuticals, Inc. Provides Sales Guidance for the Year 2024

Mirum Pharmaceuticals, Inc. to Report Q4, 2023 Results on Feb 28, 2024

CEO & Director recently sold US$157k worth of stock

Mirum Pharmaceuticals, Inc. Announces Management Changes

Mirum Pharmaceuticals, Inc. Announces Management Appointments

Mirum Pharmaceuticals, Inc. Provides Earnings Guidance for Fourth Quarter 2023 and Full Year 2023

There's Reason For Concern Over Mirum Pharmaceuticals, Inc.'s (NASDAQ:MIRM) Price

Price target decreased by 12% to US$48.30

Mirum Pharmaceuticals, Inc. Announces Data from EMBARK Phase 2b Study for Biliary Atresia

Mirum Pharmaceuticals, Inc. Presents New Data at the Liver Meeting

Forecast breakeven date pushed back to 2025

Price target decreased by 7.2% to US$53.57

Mirum Pharmaceuticals, Inc. has filed a Follow-on Equity Offering in the amount of $200 million.

Third quarter 2023 earnings: EPS and revenues exceed analyst expectations

Mirum Pharmaceuticals, Inc. has filed a Follow-on Equity Offering in the amount of $200 million.

Consensus estimates of losses per share improve by 22%

Mirum Pharmaceuticals, Inc. Announces New PDUFA Date for LIVMARLI for the Treatment of Cholestatic Pruritus in Progressive Familial Intrahepatic Cholestasis

Mirum Pharmaceuticals, Inc. Presents LIVMARLI Clinical Data and Real-World Evidence at NASPGHAN

Mirum Pharmaceuticals, Inc. Announces Positive Phase 3 Restore Study Results Evaluating Chenodal in Patients with Cerebrotendinous Xanthomatosis

Price target increased by 7.1% to US$59.20

Insider recently bought US$296k worth of stock

Mirum Pharmaceuticals, Inc. Appoints Eric Bjerkholt as the Chief Financial Officer

Mirum Pharmaceuticals, Inc. (NasdaqGM:MIRM) completed the acquisition of Bile Acid Product Portfolio from Travere Therapeutics, Inc. (NasdaqGM:TVTX).

Second quarter 2023 earnings: Revenues exceed analysts expectations while EPS lags behind

Mirum Pharmaceuticals, Inc. to Report Q2, 2023 Results on Aug 03, 2023

Mirum Pharmaceuticals's LIVMARLI Now Authorized in Canada for Cholestatic Pruritus in Patients with Alagille Syndrome

Forecast breakeven date moved forward to 2024

Mirum Pharmaceuticals, Inc. announced that it expects to receive $210 million in funding from Frazier Life Sciences Management, LP, Avidity Partners Management, L.P., BVF Partners L.P., Longitude Capital Management Co., LLC, Sofinnova Investment, Inc. and another investor

President recently sold US$141k worth of stock

Mirum Pharmaceuticals, Inc. Showcases Five New LIVMARLI (maralixibat) Presentations at the EASL Congress

New major risk - Financial position

What Mirum Pharmaceuticals, Inc.'s (NASDAQ:MIRM) P/S Is Not Telling You

Mirum Pharmaceuticals, Inc. Announces Data from It's LIVMARLI Studies Presented at ESPGHAN Annual Meeting

Mirum Pharmaceuticals, Inc. Announces Hepatology Communications Publishes Data from CAMEO Study Evaluating Safety, Tolerability, and Efficacy of LIVMARLI® (Maralixibat) Oral Solution in Patients with Primary Sclerosing Cholangitis

Mirum Pharmaceuticals, Inc. Announces Enrollment Completion in Phase 2b EMBARK Biliary Atresia Study

No longer forecast to breakeven

Industry Analysts Just Made A Captivating Upgrade To Their Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM) Revenue Forecasts

Consensus revenue estimates increase by 16%

Mirum Pharmaceuticals Submits Supplemental New Drug Application to FDA for LIVMARLI in Patients with Cholestatic Pruritus in Progressive Familial Intrahepatic Cholestasis

Mirum Pharmaceuticals, Inc. Announces Resignation of Ian Clements as Chief Financial Officer

Forecast to breakeven in 2025

Mirum Pharmaceuticals, Inc. Announces Resignation of Carol L. Brosgart, M.D. as A Director of the Company and as A Member of the Nominating and Corporate Governance Committee of the Board, Effective December 19, 2022

Mirum Pharmaceuticals, Inc. Appoints Lon Cardon to Board of Directors

Mirum Pharmaceuticals, Inc. Announces LIVMARLI (maralixibat) Approval by the European Commission for the Treatment of Cholestatic Pruritus in Patients with Alagille Syndrome Two Months and Older

Mirum Pharmaceuticals Provides Development Program Updates

Forecast to breakeven in 2024

Mirum Pharmaceuticals, Inc. to Report Q3, 2022 Results on Nov 09, 2022

Mirum Pharmaceuticals, Inc. Reports Positive Topline Data from Its Phase 3 March Study

過去基準チェック /06